Document is current
Any future updates will be listed below
-
Authors
Guillen-Sola, Anna https://orcid.org/0000-0001-8442-8968
Soler, Neus Bofill
Marco, Ester
Pera-Cegarra, Oscar
Foro, Palmira
-
Funding
Funding for this research was provided by:
Fundación Científica Asociación Española Contra el Cáncer (PS2014)
- License Information
-
More Information
Article History
Received: 14 March 2019
Accepted: 16 July 2019
First Online: 14 August 2019
Ethics approval and consent to participate
: National and international research ethics guidelines will be followed, including the Deontological Code of Ethics, Declaration of Helsinki, and current confidentiality laws concerning personal data in Spain (<i>Ley Orgánica 03/2018</i>, 5 December) and the European Union (<i>European Parliament and Council Regulation EU 2016/619</i>). The Redyor study protocol and the informed consent process have been reviewed and approved by the Clinical Ethics Committee of the Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain (Comité Ètic d’Investigació Clínica Parc de Salut Mar: reference number 2015/6288/I) (Additional file 2). Standard Protocol followed SPIRIT guidelines will be followed throughout (Additional file ) and the trial was registered at with code NCT0209009911 on February 9, 2016. Informed consent (Additional file 1) was obtained from all individual participants included in the study.
: The authors declare that they have no competing interests.
